Immatics Biotechnologies社、Genedata Biologicsを導入：
抗体、T細胞療法の研究開発を効率化

Leading immuno-oncology company adopts Genedata Biologics® to support the discovery and development of TCRs for adoptive cell therapies and bispecific TCR molecules

November 12, 2019
Basel, Switzerland

Genedata, the leading provider of enterprise software solutions for biopharmaceutical R&D, today announced that Immatics Biotechnologies, a clinical-stage biopharmaceutical company developing T-cell receptor (TCR)-based cancer immunotherapies, has adopted Genedata Biologics^® to streamline their R&D operations related to the discovery and development of high-affinity and high-specificity T-cell receptors for adoptive cell therapies (ACT) and bispecific TCRs.

“We required a scalable software solution that is compatible with Immatics’ proprietary XCEPTOR® platform to facilitate the systematic analysis of our TCR data for our proprietary and partnered programs,” said Dominik Maurer, Ph.D., VP Immunology at Immatics. “Genedata Biologics gives all our R&D groups a central place to record and access TCR-related information in real time, along the end-to-end workflow, including Immatics’ ACTengine^®, ACTallo^® and TCER^® bispecific TCR molecule development. We expect Genedata Biologics to foster our internal information exchange and further increase our efficiency.”

Integrated E2E Workflow Platform for Cell & Gene Therapy
As highly engineered entities, bispecific molecules and cell and gene therapies pose new design, cloning, expression, purification, and analytics challenges. Genedata Biologics provides purpose-built functionality for the design and evaluation of large panels of novel cellular modalities, such as engineered TCRs and their variations. In particular, the platform enables the automation of screening, engineering, production, and testing of these innovative therapeutic modalities. The workflow platform handles next-generation molecule-specific designs in high throughput and includes dedicated tools for developability and manufacturability assessments. Genedata Biologics is an end-to-end (E2E) platform that streamlines the design, generation, validation, and unique identification of TCR- based molecules, resulting in more efficient evaluation and production.

“We are excited that Immatics, a leader in immuno-oncology, has selected Genedata as their partner,” said Othmar Pfannes, Ph.D., CEO of Genedata.  “We are delighted that Genedata Biologics helps our customers to increase the efficiency of the discovery and development of novel gene and cellular therapeutics, and we will continue to invest in expanding the platform’s capabilities to address new technologies and requirements in this quickly evolving field.”